April 1, 2013

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.

.   .   

This small retrospective study analyzed the efficacy and safety of rituximab in adults with steroid-dependent minimal change disease. Of the seventeen relapsing steroid-dependent patients treated with rituximab, eleven had no relapses with nine being able to come off all other drugs during the mean 29.5 month follow-up period. This sets the stage for a prospective randomized controlled trial.

Related Articles:

Clinical Nephrology, Glomerulonephritis

Comments are closed.